Targeting Bcl-2 stability to sensitize cells harboring oncogenic ras

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Bcl-2 family proteins regulate apoptosis.
• Oncogenic ras-driven cells are sensitive to protein kinase C (PKC) inhibition.
• Bcl-2 antagonizes apoptosis induced by PKC inhibition, but its regulation is unclear.

Purpose of the Study:

• Investigate Bcl-2 stability in sensitizing cells with oncogenic K-ras to apoptosis.
• Examine the role of Bcl-2 degradation in response to PKC inhibitor GO6976.

Main Methods:

• Utilized Swiss3T3 and murine lung cancer LKR cells expressing oncogenic K-ras.
• Treated cells with PKC inhibitor GO6976.
• Analyzed Bcl-2 ubiquitination and degradation pathways.
• Investigated Bcl-2 complex formation with Keap-1 and Cul3.
• Performed site-directed mutagenesis on Bcl-2 (serine-17, BH-2, BH-4 domains).

Main Results:

• GO6976 treatment induced rapid, ubiquitin-dependent proteasome degradation of Bcl-2.
• Bcl-2 degradation was accompanied by apoptosis induction.
• Bcl-2 formed a complex with Keap-1 and Cul3 during degradation.
• Mutations at serine-17 or deletion of BH-2/BH-4 domains impaired Bcl-2 ubiquitination and degradation.
• Impaired degradation elevated the apoptosis induction threshold.

Conclusions:

• Bcl-2 stability is regulated by ubiquitin-dependent proteasome pathway following PKC inhibition.
• Bcl-2 degradation is essential for apoptosis induction in K-ras-driven cancer cells.
• Targeting Bcl-2 stability offers a potential therapeutic strategy for K-ras-driven cancers.